Irinotecan Hydrochloride Injection shortage
Irinotecan Hydrochloride Injection is currently listed in shortage by the FDA. The FDA lists 4 affected products. This page was last refreshed from FDA data on Sep 19, 2026.
Ingenus Pharmaceuticals and Jiangsu Hengrui are permanently stopping production of irinotecan hydrochloride injection — a chemotherapy medicine — and no supply from either maker is currently available. Other manufacturers, including the maker of Camptosar (irinotecan hydrochloride), still list this medicine as available.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Irinotecan Hydrochloride Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Feb 24, 2026Currently in shortage4 of 4 products affected.
-
Feb 24, 2026More presentations reported2 more products added to the shortage.
-
Sep 26, 2025First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Ingenus Pharmaceuticals LLC 📞 866-321-5031 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 50742-402-05) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 50742-401-02) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
Manufacturer: Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) 📞 Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.) 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02) | — | — | Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals | — |
| To Be Discontinued | Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 25021-230-05) | — | — | Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals | — |
These rows are manufacturer reports to the FDA for Irinotecan Hydrochloride Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Irinotecan Hydrochloride Injection? options further down this page.
Why is Irinotecan Hydrochloride Injection in shortage?
Two manufacturers that make irinotecan hydrochloride injection are permanently stopping production of their versions of this medication. Ingenus Pharmaceuticals has made a business decision to discontinue both their 40 mg/2 mL and 100 mg/5 mL vials. Separately, Jiangsu Hengrui Pharmaceuticals (whose product was distributed by Sagent Pharmaceuticals) is also permanently discontinuing their 40 mg/2 mL and 100 mg/5 mL vials.
Neither manufacturer shared a specific public reason beyond it being a business or manufacturing discontinuation decision. It's worth knowing that this report only covers these two manufacturers — it doesn't mean irinotecan is going away entirely, as other companies may still be producing it and are listed separately.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Irinotecan Hydrochloride Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Irinotecan Hydrochloride Injection?
Irinotecan Hydrochloride Injection is currently on the FDA drug-shortage list. Because this medicine is given by injection, it is usually handled by a cancer clinic or infusion pharmacy, so please share this note with the team that manages your treatment.
Two strengths are covered by this report, and both are affected. Right now, neither the 40 mg/2 mL nor the 100 mg/5 mL strength has an available source from the manufacturers on this record. Both are listed as to be discontinued, based on a business decision by those makers rather than any safety or quality problem. Because these are discontinuations, this particular supply problem may be permanent for these products.
Importantly, this report reflects only the two manufacturers that filed it. Other companies still make irinotecan in a 20 mg/mL solution, so the medicine itself is not gone from the market.
Here is what I suggest:
- Do not stop, skip, or change your treatment on your own — your care team will manage timing and dosing.
- Ask your clinic or pharmacy to check wholesalers and other manufacturers; the same medicine (irinotecan 20 mg/mL) is available from several makers, though it may not be in local stock.
- Ask your prescriber or pharmacist about a clinician-chosen option if your product cannot be found.
Manufacturer contact numbers are listed on this page for reference. This is general, national information and may not match your clinic's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Irinotecan Hydrochloride Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Irinotecan Hydrochloride Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Camptosar | IRINOTECAN HYDROCHLORIDE 20 mg/mL | Injection, Solution · Intravenous | Pharmacia & Upjohn Company LLC | 00009-0082-02 |
| Irinotecan Hydrochloride | IRINOTECAN HYDROCHLORIDE 20 mg/mL | Injection · Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9583-01 |
| Irinotecan Hydrochloride | IRINOTECAN HYDROCHLORIDE 20 mg/mL | Injection · Intravenous | Northstar Rx LLC | 16714-0027-01 |
| Irinotecan Hydrochloride | IRINOTECAN HYDROCHLORIDE 20 mg/mL | Injection, Solution · Intravenous | Actavis Pharma, Inc. | 45963-0614-51 |
| Irinotecan Hydrochloride | IRINOTECAN HYDROCHLORIDE 20 mg/mL | Injection, Solution · Intravenous | Eugia US LLC | 55150-0352-01 |
| Irinotecan Hydrochloride | IRINOTECAN HYDROCHLORIDE 20 mg/mL | Injection, Solution · Intravenous | Apotex Corp. | 60505-6128-00 |
| Irinotecan Hydrochloride | IRINOTECAN HYDROCHLORIDE 20 mg/mL | Injection, Solution · Intravenous | Hospira, Inc. | 61703-0349-09 |
| Irinotecan Hydrochloride | IRINOTECAN HYDROCHLORIDE 20 mg/mL | Injection, Solution · Intravenous | Fresenius Kabi USA, LLC | 63323-0193-52 |
| Irinotecan Hydrochloride | IRINOTECAN HYDROCHLORIDE 20 mg/mL | Injection, Solution · Intravenous | Qilu Pharmaceutical Co., Ltd. | 67184-0511-01 |
| Irinotecan Hydrochloide | IRINOTECAN HYDROCHLORIDE 20 mg/mL | Injection · Intravenous | BluePoint Laboratories | 68001-0480-22 |
| Irinotecan Hydrochloide | IRINOTECAN HYDROCHLORIDE 20 mg/mL | Injection · Intravenous | Xiromed LLC | 70700-0169-22 |
Therapeutic equivalents & pricing 28 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Camptosar 20 mg/mL | Pharmacia | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Hikma | 5 ml | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Hikma | 5 ml | — | AP | FDA listed |
| Irinotecan hydrochloride 20 mg/mL | Northstar | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Sagent | 1 vial | — | — | FDA listed |
| Irinotecan hydrochloride 20 mg/mL | Actavis | 1 vial | — | AP | Discontinued |
| Irinotecan Hydrochloride 100 mg/5mL | Ingenus | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Eugia | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Apotex | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Apotex | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Hospira, | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Fresenius | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Qilu | 1 vial | — | AP | FDA listed |
| Irinotecan hydrochloide 20 mg/mL | BluePoint | 1 vial | — | AP | FDA listed |
| Irinotecan hydrochloride 20 mg/mL | Gland | 1 vial | — | AP | FDA listed |
| Irinotecan hydrochloride 20 mg/mL | Xiromed | 1 vial | — | AP | FDA listed |
| Camptosar 20 mg/mL | Pharmacia | 1 vial | — | AP | Discontinued |
| Irinotecan Hydrochloride 20 mg/mL | Hikma | 2 ml | — | AP | FDA listed |
| Irinotecan hydrochloride 20 mg/mL | Northstar | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 40 mg/2mL | Ingenus | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Eugia | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Eugia | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Qilu | 1 vial | — | AP | FDA listed |
| Irinotecan hydrochloide 20 mg/mL | Gland | 1 vial | — | AP | FDA listed |
| Irinotecan hydrochloide 20 mg/mL | Xiromed | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Qilu | 1 vial | — | AP | FDA listed |
| Camptosar 20 mg/mL | Pharmacia | 1 vial | — | AP | FDA listed |
| Irinotecan Hydrochloride 20 mg/mL | Eugia | 1 vial | — | AP | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Irinotecan Hydrochloride Injection — that fall in the same broad treatment class (antineoplastic - topoisomerase i inhibitors) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other oncology shortages
Irinotecan Hydrochloride Injection shortage FAQs
Is Irinotecan Hydrochloride Injection in shortage?
Which products are affected?
When will Irinotecan Hydrochloride Injection be available again?
Can I still get Irinotecan Hydrochloride somewhere?
What should I do if I take Irinotecan Hydrochloride Injection?
Still have a question about the Irinotecan Hydrochloride Injection shortage?
Ask a pharmacist about this shortage →View Irinotecan Hydrochloride Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.